College of Medicine / Residencies / Psychiatry / Daniel Kantor, M.D.

Daniel Kantor, M.D. 

Core Faculty and Neurologist, Kantor Neurology


placeholder
 
 
Current Profesional Activities / Committees
  • [2016 - Present] Editorial Advisory Board Practical Neurology
  • [2016 - Present] Medical Advisory Board Univadis
  • [2014 - Present] Journal Reviewer Cognitive and Behavioral Neurology
  • [2013 - 2014] Editor-in-Chief Proceedings of the Florida Society of Neurology
  • [2010 - Present] Journal Reviewer Neurology
  • [2009 - Present] Journal Reviewer International Journal of MS CareSelected Bibliography - Most representative
Peer Reviewed Publications / Journal Articles from the last 5 years

 

  • Kantor D, Sotirchos ES and Calabresi PA. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology.
  • 2016 Sep 27;87(13):1424.
  • Anderson J, Bell C, Bishop J, Capila I, Ganguly T, Glajch J, Iyer M, Kaundinya G, Lansing J, Pradines J, Precott J, Cohen BA, Kantor D, Sachleben
  • R. Demonstration of equivalence of a generic glatiramer acetate (GlatopaTM). Journal of the Neurological Sciences 359 (2015): 24-34.
  • D'Alessandro JS, Duffner J, Pradines J, Capila I, Garofalo K, Kaundinya G, Greenberg BM, Kantor D, Ganguly TC. Equivalent Gene Expression
  • Profiles between Glatopa™ and Copaxone®. PLoS One. 2015 Oct 16;10(10):e0140299.
  • Kantor D, Panchal S, Patel V, Bucior I, Rauck R. Treatment of Postherpetic Neuralgia With Gastroretentive Gabapentin: Interaction of Patient
  • Demographics, Disease Characteristics, and Efficacy Outcomes. J Pain. 2015 Dec;16(12):1300-11.
  • Hughes B, Cascione M, Freedman MS, Agius M, Kantor D, Gudesblatt M, Goldstick LP, Agashivala N, Schofield L, McCague K, Hashmonay R,
  • Barbato L; EPOC study investigators. First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label,
  • multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Mult Scler Relat Disord. 2014 Sep;3(5):620-8.
  • Bermel RA, Hashmonay R, Meng X, Randhawa S, von Rosenstiel P, Sfikas N, Kantor D. Fingolimod first-dose effects in patients with relapsing
  • multiple sclerosis concomitantly receiving selective serotonin-reuptake inhibitors. Multiple Sclerosis and Related Disorders. 2015 Apr;4(3):273-280.
  • Kantor D, Chancellor MB, Snell CW, Henney HR, Rabinowicz AL. Assessment of confirmed urinary tract infection in patients treated with
  • dalfampridine for multiple sclerosis. Postgrad Med. 2015 Feb;127(2):218-22.
  • Calkwood J, Cree B, Crayton H, Kantor D, Steingo B, Barbato L, Hashmonay R, Agashivala N, McCague K, Tenenbaum N, Edwards K. Impact of a
  • switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple
  • sclerosis: post hoc analyses of the EPOC trial. BMC Neurol. 2014 Nov 26;14(1):220.
  • Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A; ADVANCE Study
  • Investigators (Kantor D). Pegylated interferon ß-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
  • Lancet Neurol. 2014 Jul;13(7):657-65.
  • Leist T, Hunter SF, Kantor D, Markowitz C. Novel therapeutics in multiple sclerosis management: clinical applications. Am J Med. 2014
  • Jan;127(1):S2

 

Participation in Local, Regional, and National Activities / Presentations / Abstracts / Grants from the last 5 years:
  • Kantor D, Johnson K, Vieira M, Signorovitch J, Li N, Gao W, Koo V, Duchesneau E, Herrera V. Real-World Persistence with Fingolimod for the Treatment of Multiple Sclerosis: A Systematic Review and Meta-analysis: Academy of Managed Care Pharmacy Nexus 2016. National Harbor, MD, October 2016 (Poster G13). *Bronze Medal Winning Abstract.
  • Kantor D, Ko J, Antol D, Casebeer A, Stemkowski S, Cave J, Herrera V. The Impact of Step Therapy on Oral Disease-Modifying Treatment Initiation Rates for Patients with Multiple Sclerosis: Academy of Managed Care Pharmacy Nexus 2016. National Harbor, MD, October 2016 (Poster G15).
  • Kantor D, Shafrin J, Michalopoulos S, Fuhr J, Ko J, Herrera V, Goldman D. Imagining a World Without Disease-Modifying Therapies: Advancements in Outcomes for Patients with Multiple Sclerosis Between 1993 and 2016: Academy of Managed Care Pharmacy Nexus 2016. National Harbor, MD, October 2016 (Poster G16).
  • Kantor D. Number needed to treat (NNT) analysis of confirmed disability improvement across multiple sclerosis monoclonal antibody disease modifying agents clinical trials: 32nd Congress of the European Committee for Treatment and Research in MS. London, September 2016 (Late= Breaking Poster P1668).
  • Kantor D, Hunter SF, Dentiste A, Aikman M, Tyle P and Kaba S. A randomized, double-blind, parallel group study to compare the safety and efficacy of arbaclofen extended release tablets to placebo and baclofen for the treatment of spasticity in patients with multiple sclerosis: 32nd
  • Congress of the European Committee for Treatment and Research in MS. London, September 2016 (Oral presentation 128).
  • Oliveria SF, Rodriguez RL, Kantor D, Bowers D, Monari EH, Scott BM, Okun MS, Foote KD. A randomized trial of dual lead thalamic dbs for the treatment of multiple sclerosis tremor: results from the NIH cohort: 32nd Congress of the European Committee for Treatment and Research in MS. London, September 2016 (Oral presentation 129).
  • L, Kantor D, Derwenskus J, Hunter, SF. Serious adverse events (SAE), autoimmunity(AI), and infections following Alemtuzumab therapy in a large, high disability, treatment-refractory MS clinic cohort: 32nd Congress of the European Committee for Treatment and Research in MS. London, September 2016 (Poster 1182).
  • Burtchell J and Kantor D. Use of social media and the Internet among patients with multiple sclerosis: 32nd Congress of the European Committee for Treatment and Research in MS. London, September 2016 (ePoster EP1553).
  • Hunter SF, Kantor D, Dentiste A, Aikman M, Tyle P and Kaba S. A One Year, Open Label, Dose Escalation Study to Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects with Spasticity: 32nd Congress of the European Committee for Treatment and Research in MS. London, September 2016 (ePoster EP1564).
  • Kantor D. Pneumonitis as an early adverse event of alemtuzumab: The First Case Report: 32nd Congress of the European Committee for Treatment and Research in MS. London, September 2016 (ePoster EP1531).